98%
921
2 minutes
20
We report a Danio rerio transposon named DrTRT, for D. rerio Transposon Related to Tc1 The complete sequence of the DrTRT transposon is 1,563 base pairs (bp) in length, and its transposase putatively encodes a 338-amino acid protein that harbors a DD37E motif in its catalytic domain. We present evidence based on searches of publicly available genomes that TRT elements commonly occur in vertebrates and protozoa. Phylogenetic and functional domain comparisons confirm that TRT constitutes a new subfamily within the Tc1 family. Hallmark features of having no premature termination codons within the transposase, the presence of all expected functional domains, and its occurrence in the bony fish transcriptome suggest that TRT might have current or recent activity in these species. Further analysis showed that the activity of TRT elements in these species might have arisen about between 4 and 19 Ma. Interestingly, our results also implied that the widespread distribution of TRT among fishes, frog, and snakes is the result of multiple independent HT events, probably from bony fishes to snakes or frog. Finally, the mechanisms underlying horizontal transfer of TRT elements are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630946 | PMC |
http://dx.doi.org/10.1093/gbe/evw213 | DOI Listing |
J Anim Sci
January 2025
Department of Animal Science, Iowa State University, Ames, IA, USA50011.
Soybeans contain trypsin inhibitor proteins that are antinutritional and may result in growth performance inhibition through reduced amino acid bioavailability. The objective of this experiment was to determine the level of active trypsin inhibitor units (TIU) per milligram (TIU/mg) of complete feed that leads to reductions in growth performance and nitrogen digestibility. Forty-five grower gilts (39.
View Article and Find Full Text PDFAppl Radiat Isot
November 2025
Legnaro National Laboratories, National Institute for Nuclear Physics, INFN-LNL, Viale dell' Università 2, 35020 Legnaro, Italy.
The ISOLPHARM project of the INFN aims to study the properties of the Ag β emitter as a promising core for novel radiopharmaceuticals. Ag will be produced at the SPES facility of the Legnaro National Laboratories, with high specific activity and remarkable yields, exploiting the ISOL technique. This work presents Monte Carlo dosimetry calculations at cellular level to assess the therapeutic potential of Ag within the ADMIRAL project.
View Article and Find Full Text PDFNucleic Acids Res
July 2025
Section on Molecular and Cell Biology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Intramural Research Program, National Institutes of Health, Bethesda, MD 20892, United States.
RNA polymerase III (Pol III) and some of its small non-coding RNAs have been co-opted by the immune system. We discovered a non-canonical activity for a human tRNA gene, TRT-TGT4-1, robust activation of interferon-stimulated gene (ISG) response after transfection into HEK293T cells, dependent on Pol III promoter-directed transcription and its flanking sequences. The activity requires the pattern recognition receptor RIG-I, which is activated by short RNAs with 5'-triphosphate (5'ppp).
View Article and Find Full Text PDFQ J Nucl Med Mol Imaging
June 2025
Division of Nuclear Medicine, Department of Radiation Medicine, University of Cape Town, Cape Town, South Africa -
With the growth and surge of prostate cancer theranostics globally, multiple targeted radionuclide therapy (TRT) agents have been utilized to aim to provide a tumoricidal effect to patients who would benefit from TRT. Despite the fact that approved isotopes such as Strontium-89, Samarium-153 and Radium-223 exist, Lutetium-177 prostate specific membrane antigen (PSMA) has revolutionized the impact of radioligand therapy (RLT) in this domain. Key defining clinical trials such as the VISION, TheraP and PSMAfore trials have given clear evidence of the benefit of PSMA RLT in the treatment landscape of metastatic castrate resistant prostate cancer.
View Article and Find Full Text PDFMol Pharm
July 2025
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Jiangyang District, Luzhou 646000, Sichuan, China.
Prostate-specific membrane antigen (PSMA) targeted radioligand therapy (TRT) for metastatic castration-resistant prostate cancer has demonstrated significant potential. This study aimed to develop an optimal radiotherapeutic agent suitable for high-level PSMA expression by optimizing the ligand structure with albumin-binding zwitterionic strategies to increase tumor uptake and retention time and to explore the effects of these strategies on the in vitro and in vivo properties of PSMA inhibitors. All precursors were synthesized based on PSMA-targeting agent Flu-1.
View Article and Find Full Text PDF